Health Professionals / Chronic lymphocytic leukemia and prolymphocytic leukemia
Chronic lymphocytic leukemia and prolymphocytic leukemia
Indications
- 17p-: when initiation of treatment indicated, patient should received immuno-chemotherapy followed by first line allogeneic SCT.
- Recurrent disease < 12 months post fludarabine based treatment
- Recurent disease < 24 months post combined immuno-chemotherapy (ex.: RF, RFC, FC)
Eligibility
- Related transplant: < 66 years
- Unrelated transplant: < 61 years
Pre-transplant chemotherapy
- 17p: non bulky disease (< 5cm) Campath; bulky disease FCR followed by Campath if persistence of significant disease
- Without 17p: FCR unless progressive disease within 12 months of FCR